Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
Five things for pharma marketers to know: Thursday, September 7, 2017
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Back at Dendreon, Caggiano takes on Provenge’s comeback
Sales of Merck’s Keytruda double in the first quarter; the FDA approves AstraZeneca’s immunotherapy; Lilly’s insulin is under investigation in two states
Merck’s DTC ad for Keytruda hints at more cancer brands turning to TV